Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (189)	11/3/2005 11:53:28 PM
From: scaram(o)uche	Respond to of 930

A261 A Phase 1 Dose-escalation and Pharmacokinetic (PK) Study of a Novel Spectrum-selective Kinase Inhibitor (SSKI), XL647, in Patients with Advanced Solid Malignancies. Heather Wakelee, Alex A. Adjei, Joanne Halsey, Janet Lensing, Julia Dugay, Lorelei Hanson, Joel Reid, Sylvia Hutchison, Jill Piens, Branimir I. Sikic. (Tuesday afternoon, 12:30 pm Eastern) A245 A Phase 1 Study of a Novel Spectrum Selective Kinase Inhibitor (SSKI), XL880, Administered Orally in Patients with Advanced Solid Malignancies. Patricia LoRusso, Leonard Appleman, Elizabeth Heath, Lauren Malburg, Andrew X. Zhu, Martin Carey, Geoffrey I. Shapiro, Joseph P. Eder. (ditto) C82 A Phase 1 Dose-escalation and Pharmacokinetic (PK) Study of a Novel Spectrum Selective Kinase Inhibitor (SSKI), XL999, in Patients with Advanced Solid Malignancies. Kyriakos P. Papadopoulos, Monica M. Mita, Janet Curtright, Afshin Dowlati, Susan Flick, Alejandro Ricart, Chris Takimoto, Harold Keer, Josh Cooper. (ditto, except Thursday)